Journey Medical (DERM) Price to Sales (2021 - 2026)

Journey Medical (DERM) has reported Price to Sales for 6 consecutive years, with 10.52 the latest figure, recorded in Q2 2026.

• For the quarter ending Q2 2026, Price to Sales fell 5.62% year-over-year to 10.52; the trailing twelve-month figure through Jun 2026 stood at 2.85 (down 3.72% YoY), and the FY2025 full-year result was 2.64, up 85.19% from the prior year.
• Price to Sales rose to 10.52 in Q2 2026 per DERM's latest filing, from 8.02 in the prior quarter.
• Across five years, Price to Sales topped out at 11.14 in Q2 2025 and bottomed at 1.46 in Q3 2023.
• Historically, Price to Sales has averaged 6.08 across 5 years, with a median of 6.37 in 2024.
• The sharpest annual moves came in 2023 and 2024: Price to Sales slumped 53.29% in 2023, then soared 442.93% in 2024.
• Over 5 years, Price to Sales stood at 2.11 in 2022, then soared by 226.5% to 6.88 in 2023, then fell by 14.79% to 5.87 in 2024, then jumped by 72.86% to 10.14 in 2025, then rose by 3.72% to 10.52 in 2026.
• According to Business Quant data, Price to Sales over the past three periods registered 10.52, 8.02, and 10.14 for Q2 2026, Q1 2026, and Q4 2025 respectively.